Combination of pegylated interferon‐alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients | Zendy

Pang X. | Zendy; Zhang L. | Zendy; Liu N. | Zendy; Liu B. | Zendy; Chen Z. | Zendy; Li H. | Zendy; Chen M. | Zendy; Peng M. | Zendy; Ren H. | Zendy; Hu P. | Zendy

Open Access

Combination of pegylated interferon‐alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients

Author(s) -

Pang X.,

Zhang L.,

Liu N.,

Liu B.,

Chen Z.,

Li H.,

Chen M.,

Peng M.,

Ren H.,

Hu P.

Publication year - 2020

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.13486

Subject(s) - hbsag , il 2 receptor , immunology , medicine , cytotoxic t cell , cd8 , interleukin 21 , hepatitis b virus , antigen , immune system , t cell , biology , virus , biochemistry , in vitro

For NA‐experienced CHB patients who achieved low HBsAg levels, a combination of Peg‐IFN‐α and NA therapy is more likely to result in HBsAg decline and HBsAg clearance by increasing the activity of CD56briNK cells. And NA therapy may restore partial immune status in CHB patients through down‐regulating the expression of CCR4 and reducing the immunosuppressive effect of Treg cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research